Literature DB >> 7873133

Lifetime risk of depression.

H U Wittchen1, B Knäuper, R C Kessler.   

Abstract

Over the past decade, major epidemiological studies have been conducted to determine the prevalence of depressive syndromes, primarily major depression or dysthymia. The highest prevalences occur in younger cohorts (18-29 years); considerably lower prevalences are found in older individuals (45 years and above), with the lowest in those aged 65 and older. Several studies have confirmed an increase in the cumulative lifetime estimates of major depression in successively younger birth cohorts during this century. At the same time, questions have been raised about the low prevalence of depression in the elderly, including the role of confounding factors (e.g. differential morbidity and response-biased memory). Standardised diagnostic assessment procedures may be insufficiently adapted for use in the elderly. It has also been recognised that a substantial number of elderly individuals suffer from clinically relevant symptoms of depression but do not meet the criteria for major depression. Future research will be required to elucidate fully the apparently changing rates of depression.

Entities:  

Mesh:

Year:  1994        PMID: 7873133

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  20 in total

Review 1.  Anxiety disorders.

Authors:  Jian-Ping Chen; Leonard Reich; Henry Chung
Journal:  West J Med       Date:  2002-09

2.  Depression and health-related quality of life for low-income African-American women in the U.S.

Authors:  Lori B Frank; Louis S Matza; Dennis A Revicki; Joyce Y Chung
Journal:  Qual Life Res       Date:  2005-12       Impact factor: 4.147

Review 3.  Pharmacogenetics of major depression: insights from level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.

Authors:  Magnus Lekman; Silvia Paddock; Francis J McMahon
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 4.  Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.

Authors:  N S Gunasekara; S Noble; P Benfield
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

Review 5.  Paroxetine. A pharmacoeconomic evaluation of its use in depression.

Authors:  M I Wilde; R Whittington
Journal:  Pharmacoeconomics       Date:  1995-07       Impact factor: 4.981

Review 6.  Tianeptine: a review of its use in depressive disorders.

Authors:  A J Wagstaff; D Ormrod; C M Spencer
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 7.  Sertraline. A pharmacoeconomic evaluation of its use in depression.

Authors:  R Davis; M I Wilde
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

Review 8.  Fluoxetine. A pharmacoeconomic review of its use in depression.

Authors:  M I Wilde; P Benfield
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

Review 9.  Genetic and environmental influences on psychiatric comorbidity: a systematic review.

Authors:  M Cerdá; A Sagdeo; J Johnson; S Galea
Journal:  J Affect Disord       Date:  2009-12-11       Impact factor: 4.839

10.  Course of illness, hippocampal function, and hippocampal volume in major depression.

Authors:  Glenda M MacQueen; Stephanie Campbell; Bruce S McEwen; Kathryn Macdonald; Shigeko Amano; Russell T Joffe; Claude Nahmias; L Trevor Young
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.